Enterprise Value

141.4M

Cash

50.69M

Avg Qtr Burn

-8.972M

Short % of Float

2.47%

Insider Ownership

5.38%

Institutional Own.

13.71%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rilvegostomig (PD-1/TIGIT) Details
Non-small cell lung carcinoma, Cancer, Hepatobiliary cancer

Phase 3

Data readout

Rilvegostomig (PD-1/TIGIT) Details
Cancer, Biliary Tract Cancer

Phase 3

Data readout

COM701 + Opdivo (nivolumab) +/- BMS-986207 Details
Ovarian cancer, Cancer, Endometrial cancer

Phase 1/2

Update

COM701 + Opdivo (nivolumab) Details
Cancer, Solid tumor/s, Metastatic breast cancer

Phase 1b

Update

COM902 (TIGIT) Details
Cancer, Advanced malignancies

Phase 1

Data readout

COM701+COM902 +Pembrolizumab Details
Cancer, Platinum-resistant ovarian cancer

Phase 1

Data readout

COM701+COM902 +Pembrolizumab Details
Cancer, Colorectal cancer

Phase 1

Data readout

COM701 (PVRIG) Details
Ovarian cancer, Colorectal cancer , Non-small cell lung carcinoma, Breast cancer, Endometrial cancer, Cancer

Failed

Discontinued